drugset / Trial / NCT01265732

A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers

NCT01265732

Phase 1 Withdrawn Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This study investigates the safety, tolerability and pharmacokinetics of PF-04191834 when respectively given orally as a single dispersion dose and a single dose of a suspension. The suspension is the test formulation and the dispersion is the formulation with which the novel preparation will be compared.

Timeline

Start
2010-12
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator PF-4191834 Small molecule 100 mg Oral
Comparator PF-4191834 Small molecule 300 mg Oral

Indications

No indication recorded.